Alder BioPharmaceuticals Company Profile (NASDAQ:ALDR)

About Alder BioPharmaceuticals

Alder BioPharmaceuticals logoAlder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response. The Company's pipeline includes ALD403, Clazakizumab and ALD1613. ALD403 is the Company's monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6), and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone (ACTH), and is being developed for the treatment of Cushing's disease. It is also developing ALD403 program for migraine prevention.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ALDR
  • CUSIP:
Key Metrics:
  • Previous Close: $31.81
  • 50 Day Moving Average: $29.50
  • 200 Day Moving Average: $25.89
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.39
  • P/E Growth: -0.49
  • Market Cap: $1.63B
  • Outstanding Shares: 50,184,000
  • Beta: 2.67
Additional Links:
Companies Related to Alder BioPharmaceuticals:

Analyst Ratings

Consensus Ratings for Alder BioPharmaceuticals (NASDAQ:ALDR) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $49.00 (51.23% upside)

Analysts' Ratings History for Alder BioPharmaceuticals (NASDAQ:ALDR)
DateFirmActionRatingPrice TargetDetails
8/23/2016Jefferies GroupReiterated RatingBuyView Rating Details
7/27/2016Brean CapitalReiterated RatingPositive$45.00View Rating Details
4/21/2016Wells Fargo & Co.Initiated CoverageOutperformView Rating Details
3/29/2016Leerink SwannReiterated RatingOutperformView Rating Details
3/29/2016Credit Suisse Group AGReiterated RatingOutperform$40.00View Rating Details
(Data available from 8/28/2014 forward)


Earnings History for Alder BioPharmaceuticals (NASDAQ:ALDR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/26/2016Q2($0.75)($0.79)$1.14 million$0.11 millionViewListenView Earnings Details
4/28/2016Q1($0.72)($0.76)$0.14 millionViewN/AView Earnings Details
2/23/2016Q4($0.65)($0.60)ViewListenView Earnings Details
11/5/2015Q315($0.51)($0.62)$0.23 millionViewN/AView Earnings Details
8/5/2015Q215($0.40)($0.46)$0.23 millionViewN/AView Earnings Details
5/7/2015Q115($0.39)($0.40)ViewListenView Earnings Details
3/4/2015Q414$0.21($0.22)$5.70 million$6.40 millionViewN/AView Earnings Details
11/3/2014Q314$0.05$0.88$14.84 million$38.75 millionViewN/AView Earnings Details
8/5/2014Q2($0.25)($0.40)$5.00 million$4.70 millionViewN/AView Earnings Details
6/18/2014Q1($5.38)$4.60 million$4.80 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Alder BioPharmaceuticals (NASDAQ:ALDR)
Current Year EPS Consensus Estimate: $-2.76 EPS
Next Year EPS Consensus Estimate: $-3.45 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.74)($0.66)($0.71)
Q2 20162($0.80)($0.78)($0.79)
Q3 20162($0.89)($0.87)($0.88)
Q4 20162($1.01)($0.93)($0.97)
(Data provided by Zacks Investment Research)


Dividend History for Alder BioPharmaceuticals (NASDAQ:ALDR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Alder BioPharmaceuticals (NASDAQ:ALDR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/15/2016Jeffrey T L SmithVPSell3,000$31.17$93,510.00View SEC Filing  
8/1/2016John A LathamInsiderSell10,000$31.19$311,900.00View SEC Filing  
7/27/2016John A LathamInsiderSell10,000$30.14$301,400.00View SEC Filing  
7/25/2016Randall C SchatzmanInsiderSell10,000$28.08$280,800.00View SEC Filing  
6/13/2016Mark James LittonInsiderSell6,000$28.94$173,640.00View SEC Filing  
6/3/2016Jeffrey T L SmithVPSell16,090$30.20$485,918.00View SEC Filing  
6/1/2016John A LathamInsiderSell10,000$30.02$300,200.00View SEC Filing  
5/31/2016Mark James LittonInsiderSell25,000$30.05$751,250.00View SEC Filing  
5/27/2016John A LathamInsiderSell6,401$30.05$192,350.05View SEC Filing  
5/24/2016Randall C SchatzmanCEOSell10,000$28.02$280,200.00View SEC Filing  
4/18/2016Randall C SchatzmanCEOSell30,000$28.07$842,100.00View SEC Filing  
1/4/2016Mark James LittoninsiderSell25,000$31.40$785,000.00View SEC Filing  
1/4/2016Randall C. SchatzmanCEOSell10,000$31.47$314,700.00View SEC Filing  
12/1/2015Jeffrey T. L. SmithVPSell4,272$37.24$159,089.28View SEC Filing  
12/1/2015John A. LathaminsiderSell4,550$37.24$169,442.00View SEC Filing  
12/1/2015Randall C. SchatzmanCEOSell10,000$37.24$372,400.00View SEC Filing  
11/30/2015Stephen M DowDirectorSell88$37.11$3,265.68View SEC Filing  
11/2/2015Jeffrey T. L. SmithVPSell3,900$33.67$131,313.00View SEC Filing  
11/2/2015John A. LathaminsiderSell4,545$33.69$153,121.05View SEC Filing  
11/2/2015Randall C. SchatzmanCEOSell10,000$33.71$337,100.00View SEC Filing  
10/1/2015Jeffrey T. L. SmithVPSell3,900$32.25$125,775.00View SEC Filing  
10/1/2015John A. LathaminsiderSell4,545$32.26$146,621.70View SEC Filing  
9/1/2015Jeffrey T. L. SmithVPSell3,900$38.50$150,150.00View SEC Filing  
9/1/2015John A. LathaminsiderSell4,545$38.52$175,073.40View SEC Filing  
8/31/2015Stephen M DowDirectorSell16,218$38.75$628,447.50View SEC Filing  
6/12/2015Larry BenedictVPSell25,454$47.46$1,208,046.84View SEC Filing  
6/4/2015John A LathamInsiderSell25,000$44.18$1,104,500.00View SEC Filing  
6/1/2015Jeffrey T L SmithVPSell3,900$41.53$161,967.00View SEC Filing  
6/1/2015John A LathamInsiderSell4,545$41.53$188,753.85View SEC Filing  
5/22/2015Jeffrey T L SmithVPSell61,818$38.86$2,402,247.48View SEC Filing  
5/21/2015Stephen M DowDirectorSell20,000$65.69$1,313,800.00View SEC Filing  
5/20/2015Stephen M DowDirectorSell8,462$40.39$341,780.18View SEC Filing  
5/18/2015Clay B SiegallDirectorSell38,181$37.62$1,436,369.22View SEC Filing  
4/1/2015Jeffrey T L SmithVPSell3,900$27.43$106,977.00View SEC Filing  
4/1/2015John A LathamInsiderSell19,045$29.54$562,589.30View SEC Filing  
3/30/2015John A LathamInsiderSell14,500$30.20$437,900.00View SEC Filing  
1/27/2015Jeffrey T L SmithVPSell3,900$28.01$109,239.00View SEC Filing  
1/27/2015John A LathamInsiderSell15,045$28.33$426,224.85View SEC Filing  
1/27/2015Randall C SchatzmanCEOSell100,000$28.42$2,842,000.00View SEC Filing  
1/26/2015Jeffrey T L SmithVPSell2,700$27.89$75,303.00View SEC Filing  
1/26/2015Mark James LittonInsiderSell5,200$28.03$145,756.00View SEC Filing  
1/26/2015Randall C SchatzmanCEOSell36,422$27.93$1,017,266.46View SEC Filing  
11/24/2014Jeffrey T L SmithVPSell29,090$16.08$467,767.20View SEC Filing  
5/13/2014A/S NovoInsiderBuy550,000$10.00$5,500,000.00View SEC Filing  
5/13/2014Alan Bruce MontgomeryDirectorBuy3,000$10.00$30,000.00View SEC Filing  
5/13/2014West 8 Limited Partne VenturesMajor ShareholderBuy250,000$10.00$2,500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Alder BioPharmaceuticals (NASDAQ:ALDR)
DateHeadline logoAlder Biopharmaceuticals (ALDR) Jumps: Stock Rises 9.6% - Yahoo Finance (NASDAQ:ALDR) - August 25 at 3:28 PM
News IconJefferies Group Reiterates Buy at Alder BioPharmaceuticals Inc. (NASDAQ: ALDR) - BNB Daily (blog) (NASDAQ:ALDR) - August 24 at 11:43 AM
News IconStock's Buzz: Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), Valeant Pharmaceuticals International, Inc. (NYSE:VRX) - Newburg Press (NASDAQ:ALDR) - August 23 at 3:27 PM logoMomentum Stocks: VeriSign, Inc. (VRSN), Alder Biopharmaceuticals Inc. (ALDR), CubeSmart (CUBE) - iStreetWire (NASDAQ:ALDR) - August 23 at 8:26 AM
News IconStock Moving Up in Session: Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) - Post News (NASDAQ:ALDR) - August 22 at 3:29 PM logoWill Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Hit $62 Price Target? - Investor Newswire (NASDAQ:ALDR) - August 20 at 3:26 PM logoAlder Biopharmaceuticals : How These Biotech Stocks are Faring? -- bluebird bio, Sage Therapeutics, Ultragenyx Pharma, and Alder Biopharma (NASDAQ:ALDR) - August 10 at 10:35 AM logoDelta Drone is in exclusive negotiations for the acquisition of substantially all of the assets of NM, LLC based in the US (NASDAQ:ALDR) - August 8 at 3:28 PM logoEvolution of the share capital and shareholdings of Delta Drone (NASDAQ:ALDR) - August 3 at 9:03 PM logoJefferies Maintains Alder Biopharmaceuticals Inc to Buy with Price ... - Trade Calls (NASDAQ:ALDR) - August 3 at 3:30 PM logoDelta Drone SA :ALDR-FR: Earnings Analysis: For the six months ended December 31, 2015 : August 3, 2016 (NASDAQ:ALDR) - August 3 at 12:00 PM
News IconFeatured Biotechnology Stocks: Halozyme Therapeutics, Inc. (NASDAQ:HALO), Alder Biopharmaceuticals Inc ... - Post Registrar (NASDAQ:ALDR) - August 2 at 3:27 PM logoRecent Trading Alert: Zoetis Inc. (NYSE:ZTS) , Alder ... - Street Updates - Street Updates (NASDAQ:ALDR) - August 2 at 8:11 AM logoALDER BIOPHARMACEUTICALS INC Financials (NASDAQ:ALDR) - July 30 at 1:04 PM logoAlder BioPharmaceuticals Inc. (ALDR) Jumps 6.13% on July 25 - (NASDAQ:ALDR) - July 27 at 12:02 PM logoHere’s What’s Important About Alder Biopharmaceuticals Inc (ALDR)’s Latest Release (NASDAQ:ALDR) - July 27 at 9:27 AM logoEdited Transcript of ALDR earnings conference call or presentation 26-Jul-16 9:00pm GMT (NASDAQ:ALDR) - July 27 at 3:56 AM logoMigraine treatment company Alder reports loss, spends more on research (NASDAQ:ALDR) - July 26 at 9:29 PM
News IconAlder BioPharmaceuticals Reports Second Quarter 2016 Financial and Operating Results (NASDAQ:ALDR) - July 26 at 9:29 PM logoAlder BioPharmaceuticals : posts 2Q loss (NASDAQ:ALDR) - July 26 at 9:29 PM logoAlder BioPharmaceuticals posts 2Q loss (NASDAQ:ALDR) - July 26 at 5:53 PM logoHere's What's Important About Alder Biopharmaceuticals Inc ... - Market Exclusive (NASDAQ:ALDR) - July 26 at 3:25 PM logoAlder BioPharma (ALDR) Announces Positive Top-Line Data from ALD403 Phase 2b (NASDAQ:ALDR) - July 26 at 12:57 PM logoHere’s What’s Important About Alder Biopharmaceuticals Inc (NASDAQ:ALDR)’s Latest Release (NASDAQ:ALDR) - July 26 at 12:57 PM logoQ2 2016 Alder Biopharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:ALDR) - July 26 at 7:07 AM logoAlder BioPharma (ALDR) Announces Positive Top-Line Data from ALD403 Phase 2b - (NASDAQ:ALDR) - July 25 at 9:28 PM logoAlder BioPharma Confirms Data For Chronic Migraine Candidate ALD403 (NASDAQ:ALDR) - July 25 at 3:57 PM logoAlder Biopharma Migraine Drug Holds Up After 6 Months (NASDAQ:ALDR) - July 25 at 2:42 PM logoAlder Reports Positive Top-Line 24-Week Data Demonstrating Persistent Migraine Prevention in Phase 2b Study of ALD403 in Patients with Chronic Migraine (NASDAQ:ALDR) - July 25 at 8:00 AM
News IconStock Up Nicely This Week: Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) - TGP (NASDAQ:ALDR) - July 23 at 3:23 PM logoIs $61 Price Target Attainable For Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR)? - Investor Newswire (NASDAQ:ALDR) - July 23 at 3:23 PM
News IconCormorant Asset Management LLC Increased Alder ... - Press Telegraph (NASDAQ:ALDR) - July 23 at 7:52 AM logoAlder BioPharmaceuticals to Host Conference Call to Discuss Second Quarter 2016 Financial and Operating Results (NASDAQ:ALDR) - July 19 at 8:00 AM logoMetLife, Inc. (NYSE:MET) Went Up 0.54%: Alder Biopharmaceuticals Inc. (NASDAQ:ALDR), Global Ship Lease, Inc ... - KC Register (NASDAQ:ALDR) - July 18 at 3:28 PM logoShares of Alder BioPharmaceuticals (ALDR) Drops by -4.19% - Trade Calls (NASDAQ:ALDR) - July 18 at 8:15 AM logoAlder BioPharmaceuticals, Inc. (ALDR) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:ALDR) - July 17 at 8:09 AM
News IconIncreased Volatility Noted on Shares of: Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) - Engelwood Daily (NASDAQ:ALDR) - July 16 at 3:23 PM
News IconShares Experiencing a Downtrend: Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) - TGP (NASDAQ:ALDR) - July 16 at 3:23 PM logoStrong Sell Calls For Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) At 0 - Investor Newswire (NASDAQ:ALDR) - July 16 at 3:23 PM logoALDER BIOPHARMACEUTICALS INC Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders (NASDAQ:ALDR) - July 15 at 5:01 PM logoAlder BioPharmaceuticals, Inc. (ALDR) Updated Price Targets - FTSE News (NASDAQ:ALDR) - July 15 at 1:59 PM logoAlder BioPharmaceuticals Inc. (ALDR) Drops 5.92% on July 13 - (NASDAQ:ALDR) - July 14 at 8:53 PM logoNew Broker Ratings For Alder BioPharmaceuticals, Inc. (ALDR) - FTSE News (NASDAQ:ALDR) - July 14 at 12:20 PM
News IconAlder Biopharmaceuticals Incorporated (NASDAQ:ALDR) Short Interest Increased By 14.89% - Consumer Eagle (NASDAQ:ALDR) - July 13 at 11:29 AM
News IconShares Moving Up Over the Past Quarter: Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) - Engelwood Daily (NASDAQ:ALDR) - July 12 at 3:27 PM
News IconStock on the Rise for the Quarter: Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) - Engelwood Daily (NASDAQ:ALDR) - July 11 at 8:12 AM logoNext Weeks Broker Price Targets For Alder BioPharmaceuticals, Inc. (ALDR) - Fiscal Standard (NASDAQ:ALDR) - July 10 at 3:23 PM logoIs $61 Within Reach For Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR)? - Investor Newswire (NASDAQ:ALDR) - July 10 at 8:12 AM
News IconCormorant Asset Management LLC Increased Alder Biopharmaceuticals INC (NASDAQ:ALDR) by $17.76 Million as ... - Press Telegraph (NASDAQ:ALDR) - July 9 at 11:30 AM
News IconInsiders are Gradually Selling Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) - Telanagana Press (NASDAQ:ALDR) - July 7 at 3:25 PM


Alder BioPharmaceuticals (NASDAQ:ALDR) Chart for Sunday, August, 28, 2016

Last Updated on 8/28/2016 by Staff